Abstract
The papers in this supplement speak to several of the issues pertinent to contemporary therapy with CCBs. The article by Dr Weir thoughtfully describes important pharmacokinetic and pharmacodynamic features of CCBs. In so doing he establishes the basis for combination CCB and ACE inhibitor therapy. Dr Frishman provides a scholarly description of the cardiovascular effects of CCBs and further elaborates on the distinctiveness of the various CCB subclasses. Finally, Dr Bakris et al. provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
